论文部分内容阅读
美国FDA近日批准Transcept制药公司生产的酒石酸唑吡坦舌下片(商品名:Intermezzo)用于治疗以夜间觉醒后难以再次入睡为特征的失眠症状,使得该药成为FDA首次批准用于该适应证的药物,但其只能被用于睡眠时间至少为4 h的患者。
US FDA recently approved the Transcept pharmaceutical company’s production of zolpidem tartrate sublingual tablets (brand name: Intermezzo) for the treatment of insomnia characterized by difficulty falling asleep again after nighttime insomnia symptoms, making the drug first approved by the FDA for the indication But it can only be used in patients who sleep for at least 4 hours.